{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:04:25Z","timestamp":1791043465692,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":761,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes. Treatment-na\u00efve patients infected with HCV genotype 1 or 4 were randomized to 24 weeks of double-blind treatment with either mericitabine 1,000 mg (N = 81) or placebo (N = 85) twice-daily (BID) in combination with pegylated interferon alpha-2a (Peg-IFN\u03b1-2a)\/ribavirin (RBV). Patients randomized to mericitabine with HCV RNA &lt;15 IU\/mL from week 4 to 22 (extended rapid virologic response; eRVR) stopped all treatment at week 24; all other patients continued Peg-IFN\u03b1-2a\/RBV to complete 48 weeks of treatment. The primary efficacy endpoint was sustained virologic response (SVR; HCV RNA &lt;15 IU\/mL after 24 weeks of treatment-free follow-up). SVR was achieved in 56.8% (95% confidence interval [CI]: 45.9-67.0) of mericitabine-treated patients and 36.5% (95% CI: 27.0-47.1) of placebo-treated patients (\u0394 = 20.3%; 95% CI 5.5-35.2). SVR rates were higher in mericitabine- than placebo-treated patients when subdivided by<\/jats:bold>\n                      <jats:bold>IL28B<\/jats:bold>\n                      <jats:bold>genotype (CC, 77.8% versus 56.0%; non-CC, 44.1% versus 16.2%) and hepatic fibrosis (noncirrhotic, 63.3% versus 41.9%; cirrhotic, 38.1% versus 21.7%). Overall relapse rates were 27.7% and 32.0% in mericitabine- and placebo-treated patients, respectively. No evidence of NS5B S282T-variant virus or phenotypic resistance to mericitabine was observed in the one patient who experienced partial response. No S282T variants were detected in any baseline samples. The safety profile of mericitabine was similar to that of, and fewer patients in the mericitabine than in the placebo group discontinued treatment for safety reasons.<\/jats:bold>\n                      <jats:bold>Conclusion<\/jats:bold>\n                      <jats:bold>: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFN\u03b1-2a\/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFN\u03b1-2a\/RBV. (HEPATOLOGY 2013;58:514\u2013523)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.26275","type":"journal-article","created":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T13:30:08Z","timestamp":1359379808000},"page":"514-523","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":43,"title":["JUMP-C: A Randomized Trial of Mericitabine Plus Pegylated Interferon Alpha-2a\/Ribavirin for 24 Weeks in Treatment-Na\u00cfVe HCV Genotype 1\/4 Patients"],"prefix":"10.1097","volume":"58","author":[{"given":"Paul J.","family":"Pockros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoky","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolland","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Tice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lou Munson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thommes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20241201","doi-asserted-by":"crossref","first-page":"14331444","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"R2-12-20241201","doi-asserted-by":"crossref","first-page":"12071217","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection.","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-12-20241201","doi-asserted-by":"crossref","first-page":"24052416","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"RU4-12-20241201","doi-asserted-by":"crossref","first-page":"11951206","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"RU5-12-20241201","doi-asserted-by":"crossref","first-page":"10141024","DOI":"10.1056\/NEJMoa1014463","article-title":"Responseguided telaprevir combination treatment for hepatitis C virus infection.","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"RU6-12-20241201","doi-asserted-by":"crossref","first-page":"24172428","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection.","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"RU10-12-20241201","doi-asserted-by":"crossref","first-page":"11871201","DOI":"10.3851\/IMP1934","article-title":"Impact of HCV proteaseinhibitorbased triple therapy for chronic HCV genotype 1 infection.","volume":"16","author":"Ferenci","year":"2011","journal-title":"Antivir Ther"},{"key":"R11-12-20241201","first-page":"937943","article-title":"Crystal structure of the RNAdependent RNA polymerase from hepatitis C virus reveals a fully encircled active site.","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat Struct Biol"},{"key":"R12-12-20241201","doi-asserted-by":"crossref","first-page":"4916449170","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to nonobligate chainterminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J Biol Chem"},{"key":"R13-12-20241201","doi-asserted-by":"crossref","first-page":"43564369","DOI":"10.1128\/AAC.00444-08","article-title":"Selected replicon variants with lowlevel in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI6130 lack crossresistance with R1479.","volume":"52","author":"Ali","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"RU14-12-20241201","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1177\/095632020601700203","article-title":"Inhibition of hepatitis C replicon RNA synthesis by betaD2deoxy2fluoro2Cmethylcytidine: a specific inhibitor of hepatitis C virus replication.","volume":"17","author":"Stuyver","year":"2006","journal-title":"Antivir Chem Chemother"},{"key":"RU15-12-20241201","doi-asserted-by":"crossref","first-page":"2981229820","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor betaD2Deoxy2fluoro2Cmethylcytidine (PSI6130) and identification of a novel active 5triphosphate species.","volume":"282","author":"Ma","year":"2007","journal-title":"J Biol Chem"},{"key":"RU17-12-20241201","doi-asserted-by":"crossref","first-page":"411423","DOI":"10.3851\/IMP2088","article-title":"Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNAdependent RNA polymerase.","volume":"17","author":"Pawlotsky","year":"2012","journal-title":"Antivir Ther"},{"key":"R18-12-20241201","doi-asserted-by":"crossref","first-page":"447462","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection.","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"R19-12-20241201","doi-asserted-by":"crossref","first-page":"21692195","DOI":"10.3390\/v2102169","article-title":"Inhibitors of the hepatitis C virus RNAdependent RNA polymerase NS5B.","volume":"2","author":"Powdrill","year":"2010","journal-title":"Viruses"},{"issue":"Suppl 4","key":"R20-12-20241201","first-page":"862A","article-title":"Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy abstract LB9.","volume":"46","author":"Reddy","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"RU21-12-20241201","first-page":"1024A","article-title":"Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior nonresponders: interim results of R7128 1500 mg BID with PEGIFN and ribavirin for 28 days abstract LB10.","volume":"48","author":"Gane","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"RU22-12-20241201","first-page":"1160A","article-title":"Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEGIFN and ribavirin: subanalysis by raceethnicity, weight, and HCV genotype abstract 1899.","volume":"48","author":"RodriguezTorres","year":"2008","journal-title":"Hepatology"},{"key":"RU23-12-20241201","doi-asserted-by":"crossref","first-page":"14671475","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM1): a randomised, doubleblind, placebocontrolled, doseescalation trial.","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"R26-12-20241201","first-page":"701A702A","article-title":"No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and PEGIFNRBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study abstract 799.","volume":"52","author":"Le Pogam","year":"2010","journal-title":"Hepatology"},{"key":"R27-12-20241201","doi-asserted-by":"crossref","first-page":"15101519","DOI":"10.1086\/656774","article-title":"RG7128 alone or in combination with pegylated interferonalpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCVinfected patients.","volume":"202","author":"Le Pogam","year":"2010","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"R28-12-20241201","first-page":"S555S556","article-title":"Interferonfree treatment with a combination of mericitabine and danoprevirR with or without ribavirin in treatmentnaive HCV genotype 1infected patients abstract 1412.","volume":"56","author":"Gane","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R29-12-20241201","first-page":"231A","article-title":"Up to 100 SVR4 rates with ritonavirboosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) peginterferon alfa2a (40KD) (P) in HCV genotype 1infected partial and null responders: results from the MATTERHORN study abstract 81.","volume":"56","author":"Feld","year":"2012","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26275","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201308000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T09:15:43Z","timestamp":1733044543000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201308000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26275","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717976572.793470828","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}